Gain a better understanding of China's policy environment, have strong new drug and generic drug registration capabilities, be able to assist overseas partners and obtain registration of imported drugs
Has a wealth of experts CFDA review resources, can provide targeted technology, regulations, reporting strategy recommendations.
Perfect project management capabilities, always ensure the efficient operation of the project and good interoperability with overseas partners.
Can be customized for the customer a viable registration strategy, to avoid potential registration risks, to ensure timely and accurate submission of information to track the review progress in order to help customers quickly complete the registration review process.
As of 2016, more than 360 clinical and manufacturing approval documents have been obtained.